Calmodulin antagonists decrease the binding of epidermal growth factor to transformed, but not to normal, human fibroblasts.
Four psychoactive agents which inhibit calmodulin activity were used to study their effect on the binding of epidermal growth factor (EGF) to normal and simian-virus-40-transformed human fibroblasts (WI38). These calmodulin antagonists decreased the binding of 125I-labelled EGF to the transformed, but not to the normal, cell in a dose-dependent manner. The mechanism of this effect appears to be due to a decrease in the apparent affinity of the plasma-membrane EGF receptor for the EGF molecule.
D002147:Calmodulin / Q000037:antagonists & inhibitors*; D002472:Cell Transformation, Viral; D002478:Cells, Cultured; D002746:Chlorpromazine / Q000494:pharmacology*; D004815:Epidermal Growth Factor / Q000378:metabolism*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology*; D006801:Humans; D007099:Imipramine / Q000494:pharmacology*; D013539:Simian virus 40; D014268:Trifluoperazine / Q000494:pharmacology*
D002147:Calmodulin; D014268:Trifluoperazine; D004815:Epidermal Growth Factor; D006220:Haloperidol; D007099:Imipramine; D002746:Chlorpromazine